WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H407483
CAS#: 1257423-87-2
Description: BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.
Hodoodo Cat#: H407483
Name: BTdCPU
CAS#: 1257423-87-2
Chemical Formula: C13H8Cl2N4OS
Exact Mass: 337.98
Molecular Weight: 339.194
Elemental Analysis: C, 46.03; H, 2.38; Cl, 20.90; N, 16.52; O, 4.72; S, 9.45
Synonym: BTdCPU
IUPAC/Chemical Name: 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea
InChi Key: NUUSUAWULNXMGF-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H8Cl2N4OS/c14-9-3-1-7(5-10(9)15)16-13(20)17-8-2-4-11-12(6-8)21-19-18-11/h1-6H,(H2,16,17,20)
SMILES Code: O=C(NC1=CC=C(Cl)C(Cl)=C1)NC2=CC=C3N=NSC3=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 339.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Burwick N, Zhang MY, de la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M,
Sanchez-Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A. The eIF2-alpha
kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017
Apr;55:23-32. doi: 10.1016/j.leukres.2017.01.007. Epub 2017 Jan 12. PubMed PMID:
28119225; PubMed Central PMCID: PMC5354961.